Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AURLUMYN vs DOXIL (LIPOSOMAL)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
Ovarian cancer after failure of platinum-based chemotherapy,AIDS-related Kaposi sarcoma,Multiple myeloma in combination with bortezomib
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life is approximately 30–40 hours, prolonging drug exposure and allowing every-4-week dosing.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily hepatically metabolized by aldo-keto reductases to doxorubicinol (active metabolite); also metabolized by cytochrome P450 (minor) and glycosidases.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Primarily hepatic metabolism and biliary excretion; urinary excretion accounts for <10% of the administered dose as unchanged drug.
Approximately 85-90% bound to serum albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Vd approximately 2.8 L/m² (not directly L/kg; low Vd indicates predominant plasma compartment retention).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Only intravenous administration; oral bioavailability is negligible.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Not established; safety and efficacy not determined in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
No specific dose adjustment recommended, but monitor for increased toxicity (e.g., cardiotoxicity, myelosuppression) due to age-related organ function decline.
None.
Cardiotoxicity: risk of myocardial damage, including acute left ventricular failure. Myelosuppression: severe, dose-limiting. Hepatic impairment: requires dose reduction. Infusion reactions: may be severe or life-threatening. Must be administered by physician experienced in cancer chemotherapy.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Cardiotoxicity (cumulative dose-dependent, monitor LVEF), myelosuppression (neutropenia, thrombocytopenia), infusion reactions (premedicate), hand-foot syndrome (palmar-plantar erythrodysesthesia), secondary malignancies, extravasation necrosis, hepatic impairment (dose adjustment), immunosuppression, embryo-fetal toxicity.
Hypersensitivity to AURLUMYN or any of its components.
Absolute: history of hypersensitivity to doxorubicin or other anthracyclines. Relative: severe hepatic impairment, severe myelosuppression, pre-existing cardiomyopathy, prior treatment with maximum cumulative doses of anthracyclines (e.g., doxorubicin >550 mg/m², liposomal doxorubicin >900 mg/m²).
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
No specific food interactions reported. Avoid grapefruit juice per general chemotherapy precautions. Maintain adequate oral hygiene; avoid spicy or acidic foods during mucositis.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Potential benefits may warrant use of the drug in pregnant women despite potential risks. First trimester: High risk of teratogenicity including major malformations (e.g., cardiovascular, neural tube defects). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Use only if clearly needed and no safer alternative.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Doxorubicin is excreted in human milk. The milk-to-plasma (M/P) ratio for doxorubicin is approximately 0.5 to 2.0 based on limited data. Because of the potential for serious adverse reactions in nursing infants from doxorubicin (e.g., myelosuppression, cardiotoxicity), discontinue breastfeeding during and for at least 3 months after the last dose of DOXIL.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Pharmacokinetic data in pregnancy are limited; however, physiological changes (e.g., increased plasma volume, hepatic clearance) may alter doxorubicin exposure. No specific dose adjustment guidelines exist. Use the standard dose based on body surface area (BSA) while closely monitoring for toxicity. Consider dose reduction if severe myelosuppression or hepatic impairment occurs. Avoid use in the first trimester if possible.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Monitor for infusion reactions; premedicate with dexamethasone and antihistamines. Palmar-plantar erythrodysesthesia (hand-foot syndrome) may require dose delay/reduction. Cumulative dose >550 mg/m² increases cardiotoxicity risk. Do not substitute with non-liposomal doxorubicin.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
Report immediately any redness, swelling, or pain on palms or soles (hand-foot syndrome).,Avoid prolonged sun exposure and use sunscreen to prevent photosensitivity.,Notify your doctor if you experience chest pain, shortness of breath, or swelling (cardiotoxicity signs).,Take anti-nausea medications as prescribed; maintain adequate hydration.,Use effective contraception during treatment and for 6 months after.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AURLUMYN vs DOXIL (LIPOSOMAL), answered by our medical review team.
AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. DOXIL (LIPOSOMAL) is a Anthracycline Antineoplastic that works by Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AURLUMYN and DOXIL (LIPOSOMAL) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. The standard adult dose of DOXIL (LIPOSOMAL) is: Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AURLUMYN and DOXIL (LIPOSOMAL) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. DOXIL (LIPOSOMAL) is classified as Category C. Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from inves. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.